Skip to content
MODAG logo — Neuroscience Solutions

MODAG

Neuroscience Solutions

Founded 2013 Germany Germany 11 employees Series A Biotechnology, Health and Wellness

General Information

Company Name MODAG
Founded Year 2013
Location Germany Germany
Employees 11
Industries Biotechnology, Health and Wellness
Funding Stage Series A
Business Model B2B, B2B2C
Revenue Model Licensing, Product Sales, Service Fee
Social

BounceWatch is an independent company data service, not affiliated with MODAG. To contact MODAG, visit modag.net.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does MODAG compare?

A PDF of MODAG and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting MODAG soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About MODAG

MODAG, founded in 2013, is a trailblazing biotechnology firm headquartered in Germany, prominently known for its focus on Neuroscience Solutions. The company specializes in the research and development of cutting-edge therapeutics and diagnostics for neurodegenerative diseases. It operates from the Hochtechnologiepark Wendelsheim with additional R&D facilities in Munich and Göttingen.

MODAG distinguishes itself through its strategic collaborations with top-tier US and European research institutions, enabling it to translate its pioneering discoveries into clinical applications swiftly. The company's interdisciplinary management team fuels its agile operations and clinical advancements. Among its notable innovations, MODAG is advancing a new oligomer modulator designed to address Multiple System Atrophy (MSA) and other synucleinopathies like Parkinson's disease with potential first-in-class, disease-modifying drugs aimed at halting progression.

Despite no recent investment recorded, MODAG's robust portfolio of patented compounds makes it an attractive prospect for investors looking to support high-impact, growth-oriented biotechnology ventures.

Business keywords: neurodegenerative diseases, therapeutics development, diagnostics innovation, synucleinopathies, Multiple System Atrophy, Parkinson's disease, disease-modifying therapies, early diagnosis, oligomer modulator, small molecule therapeutics, clinical research, patented active compounds, interdisciplinary R&D, clinical proof-of-concept

Services & Products

Development of therapeutics for neurodegenerative diseases
Innovative diagnostics for early detection
Clinical trials management
Research and development of oligomer modulators

Target Customers

Patients with Parkinson's Disease Patients with Multiple System Atrophy Healthcare professionals in neurology Pharmaceutical companies

No funding data available for MODAG yet.

MODAG Alternatives & Competitors

View All Alternatives
MODAG vs

Pioneering new horizons in neurodegenerative disease treatment by addressing protein misfolding.

Venture round
Biotechnology, Health Care
MODAG vs
Asceneuron SA
Asceneuron SA Switzerland

Targeting the root cause of neurodegeneration

Series C
20 employees
Biotechnology, Health Care
MODAG vs
Spinogenix, Inc.
Spinogenix, Inc. United States

Developing a new class of therapeutics for neurodegenerative and psychiatric diseases

4 employees
Biotechnology, Health Care

FAQ About MODAG

Neuroscience Solutions
MODAG was founded in 2013.
MODAG is headquartered in Germany.
MODAG operates in Biotechnology and Health and Wellness. Its work centres on neurodegenerative diseases, therapeutics development, diagnostics innovation and synucleinopathies. Its customers include Patients with Parkinson's Disease, Patients with Multiple System Atrophy and Healthcare professionals in neurology.
MODAG has a B2B and B2B2C business model. Its revenue comes from Licensing, Product Sales and Service Fee.
MODAG has approximately 11 employees.
MODAG offers: Development of therapeutics for neurodegenerative diseases, Innovative diagnostics for early detection, Clinical trials management, Research and development of oligomer modulators.
Top alternatives and competitors to MODAG include Kineta (Reverse Merger With Yumanity Therapeutics), Asceneuron SA, Spinogenix, Inc., Accure Therapeutics, Cognition Therapeutics, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
MODAG and Kineta (Reverse Merger With Yumanity Therapeutics) are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for MODAG, https://www.bouncewatch.com/company/modag, updated 25 September 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout